Apricoxib

Apricoxib
Identifiers
	IUPAC name 4-[2-(4-Ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide;
CAS Number	162011-90-7;
PubChem CID	9820073;
ChemSpider	7995822;
UNII	5X5HB3VZ3Z;
KEGG	D08657;
CompTox Dashboard (EPA)	DTXSID60173502 ;
Chemical and physical data
Formula	C19H20N2O3S
Molar mass	356.4387 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C;
	InChI InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23); Key:JTMITOKKUMVWRT-UHFFFAOYSA-N;

Apricoxib is an experimental anticancer drug. It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer.[1] Development was abandoned in 2015 due to poor clinical trial results.[2]

References

Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research. 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.
http://adisinsight.springer.com/drugs/800026002

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research. 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453. PMC 3777527. PMID 22829202.

[2] ttp://adisinsight.springer.com/drugs/800026002

Apricoxib

See also

References